BMJ  2004;329 (11 September), doi:10.1136/bmj.329.7466.0

MAOBIs can benefit patients with Parkinson's disease

Monoamine oxidase type B inhibitors (MAOBIs), such as selegiline, may be beneficial in patients with early Parkinson's disease. In a meta-analysis including 17 trials and 3525 patients, Ives and colleagues (p 593) found that patients taking MAOBIs had better total scores, motor scores, and activities of daily living scores on the unified Parkinson's disease rating scale at three months than patients taking placebo; they were also less likely to need additional levodopa or to develop motor fluctuations, and they were not more likely to die or experience side effects.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Article

Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients
Natalie J Ives, Rebecca L Stowe, Joanna Marro, Carl Counsell, Angus Macleod, Carl E Clarke, Richard Gray, and Keith Wheatley
BMJ 2004 329: 593. [Abstract] [Full Text] [PDF]

Access jobs at BMJ Careers
Whats new online at Student BMJ